MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐ MET Antibody‐Drug Conjugate Therapy
International Journal of Cancer · 15.11.2026 · 159 (10) · 2606-2618
DOI: 10.1002/ijc.70634 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 02.07.2026. Verfasst von Tillmann Bedau und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Adenocarcinoma, Immunoconjugates, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at varying percentage thresholds. However, robust real‐world data on MET protein expression and clinically relevant ADC‐aligned thresholds in upper GI adenocarcinomas remain limited. We profiled 1532 upper GI adenocarcinomas using the clinically validated VENTANA MET (SP44) IHC assay. MET was stratified by (i) 3+ membranous staining fractions (any, ≥ 10%, ≥ 50%) reflecting contemporary ADC eligibility concepts and (ii) H ‐score (0–300; high ≥ 150). Overall survival analyses and multivariable Cox regression analyses were performed. High MET expression was uncommon ( H ‐score ≥ 150: 2.3%; any 3+: 1.6%; ≥ 10% 3+: 1.3%; ≥ 50% 3+: 1.0%) and enriched in advanced T stage. MET IHC strongly predicted MET amplification ( H ‐score ≥ 150: 63.6% amplified vs. 2.4% in negatives; any 3+: 75.0% vs. 2.6%; all p < 0.001). Any MET 3+ staining was independently associated with inferior overall survival (adjusted HR 2.22, 95% CI 1.29–3.83). Most MET 3+ tumors lacked concurrent HER2 positivity, Claudin‐18.2 expression, or dMMR/MSI. In the largest real‐world cohort to date, MET overexpression identifies a rare, biologically aggressive subset with poor outcomes. By applying the latest MET‐ADC–relevant IHC criteria (including the ≥ 10% 3+ threshold), this study provides clinically translatable prevalence estimates and supports standardized MET testing to inform prospective MET‐directed ADC trials in upper GI adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Department of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
ORCID-Profile: Tillmann Bedau, Alexander Quaas
Zitieren
APA
Bedau, T., Zander, T., Anton Schlößer, H., Alakus, H., Mustafov, O., Büttner, R., Bruns, C., & Quaas, A. (2026). MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐ MET Antibody‐Drug Conjugate Therapy. International Journal of Cancer, 159(10), 2606-2618. https://doi.org/10.1002/ijc.70634
Vancouver
Bedau T, Zander T, Anton Schlößer H, Alakus H, Mustafov O, Büttner R, et al. MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐ MET Antibody‐Drug Conjugate Therapy. International Journal of Cancer. 2026;159(10):2606-2618. doi:10.1002/ijc.70634
BibTeX
@article{Bedau2026,
author = {Bedau, Tillmann and Zander, Thomas and Anton Schlößer, Hans and Alakus, Hakan and Mustafov, Onur and Büttner, Reinhard and Bruns, Christiane and Quaas, Alexander},
title = {MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐ MET Antibody‐Drug Conjugate Therapy},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {10},
pages = {2606--2618},
doi = {10.1002/ijc.70634}
}
EUVIMED